Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

The advent of single-cell RNA sequencing (scRNA-seq) has provided insight into the tumour
immune microenvironment (TIME). This review focuses on the application of scRNA-seq in …

Neoadjuvant immune-checkpoint blockade therapy only benefits a limited fraction of patients
with glioblastoma multiforme (GBM). Thus, targeting other immunomodulators on myeloid …

Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

Purpose: Bladder cancer treatment remains a major clinical challenge due to therapy
resistance and a high recurrence rate. Profiling intratumor heterogeneity can reveal the …

Colorectal cancer (CRC) is one of the most common cancers worldwide, which ranks third in
terms of incidence and the second leading cause of cancer-related mortality. Metabolic …

Background The tumor-promoting role of tumor microenvironment (TME) in colorectal cancer
has been widely investigated in cancer biology. Cancer-associated fibroblasts (CAFs), as …

Solid tumours comprise many different cell types organized in spatially structured
arrangements, with substantial intratumour and intertumour heterogeneity. Advances in …

The tumor microenvironment (TME) considerably influences colorectal cancer (CRC)
progression, therapeutic response and clinical outcome, but studies of interindividual …

Simple Summary Although colorectal cancer is the third most common type of cancer, its
treatment strategies still have room for improvement, as current techniques carry risks that …